rheumatology
Osteoarthritis

Better OA analgesia may come at the price of more joint damage


A novel analgesic for osteoarthritis may offer better pain relief than current options but at the risk of more progressive disease and higher rates of total joint replacement. Tanezumab, a monoclonal antibody blocking nerve growth factor,  improved pain and physical function when compared to placebo in a trial of patients with moderate to severe OA ...

Already a member?

Enter your email to keep reading.


OR